Enzyme: selenoprotein containing selenocysteine in a redox-active loop, suggesting enzymatic activity, Membrane protein: associated with the endoplasmic reticulum membrane, Single-pass transmembrane protein or monotopic membrane protein (structure debate exists; most cited as single-pass transmembrane), Adaptor/Recruiter protein: interacts with multiple protein complexes and helps in protein-protein interactions
01
Overview
Selenoprotein S (SELENOS) is a small, intrinsically disordered membrane protein localized primarily in the endoplasmic reticulum, where it functions as both a recruiter/adaptor and a potential enzyme due to its rare selenocysteine-containing loop. It plays a central role in ER-associated degradation (ERAD) by facilitating the removal of misfolded proteins, partners with p97/VCP ATPase, and anchors protein complexes to the ER membrane. SELENOS also regulates inflammation by moderating cytokine secretion (including IL-6, IL-1β, TNF-α), responds dynamically to cellular stress, and participates in signaling pathways. Its genetic and expression variance is linked to multiple diseases, including diabetes, cardiovascular disease, several cancers, and sepsis. Additionally, SELENOS is hijacked by viral infections such as SARS-CoV-2 for replication complex formation. The exact mechanisms underlying its functions are under active investigation due to the protein's inherently disordered structure and broad interactome.
Other names
SELENOSSelSSEPS1VIMPTANISAD-015SBBI8MGC2553VCP-interacting membrane proteinValosin-containing protein-interacting membrane protein
02
Mechanism of action
Hypothetical mechanisms (as no direct drugs are approved): Modulation of SELENOS expression or activity to regulate ER stress, reduce cytokine-mediated inflammation, or alter redox signaling. Targeting its protein-protein interactions (such as with p97/VCP complex) for control of proteostasis in disease states.
03
Biological functions
ER-associated degradation (ERAD): a key mediator in retrotranslocating misfolded proteins from the ER to the cytosol for degradationInflammation regulation and moderation of cytokine levelsCellular stress response: upregulated during ER and oxidative stressRecruitment of p97/VCP ATPase: for proteostasis and quality controlModeration of apoptosis: via protection against ER stress-induced apoptosisSignaling pathways: including control of transcription factors and cytokine secretionPotential roles in vesicle trafficking and glycosylation
04
Disease associations
Cardiovascular disease: genetic polymorphisms are linked to increased riskDiabetes and dyslipidemia: disease risk associated with SELENOS variantsCancer: high SELENOS expression correlates with poor prognosis in several cancersInflammation: modulation of systemic inflammatory responsesSepsis: genetic variants implicated in susceptibilitySARS-CoV-2 infection: interacts with viral replication machineryPremature birth outcomes: genetic associations
05
Safety considerations
Therapeutic challenge: The multifunctionality and wide interactome of SELENOS means that targeted inhibition might produce unintended side effects on proteostasis, immune signaling, and cellular stress responsesRedox activity involvement: Manipulation may disrupt homeostasis in oxidative stress responsesStructural complexity: Intrinsically disordered regions complicate rational drug design
06
Interacting drugs
No approved drugs currently target SELENOS directly. Research into therapeutic modulation (e.g., by influencing ER stress/inflammation pathways) is ongoing, but specific drugs or inhibitors are not established in the literature
07
Biomarkers
SELENOS mRNA/protein expression: investigated as a biomarker for ER stress, inflammation, and prognosis in cancerPolymorphisms in SELENOS gene: predictive or indicative of risk for diabetes, cardiovascular diseases, and inflammatory conditions
Beyond the preview
Go deeper on Selenoprotein S (SELENOS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selenoprotein S (SELENOS).